drugset / Trial / NCT02908035

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

NCT02908035

Phase 2 Unknown 100 enrolled Mercator MedSystems, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a prospective, multi-center, randomized, dose escalation study to document the effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).

Timeline

Start
2017-03-03
Primary completion
2020-09
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Temsirolimus Small molecule 0.1 mg/ml Other
Comparator Temsirolimus Small molecule 0.4 mg/ml Other

Indications